Analyses | Innovation and technology development | 2014-07-07 | Sing Tao

Regulating biosimilars



Following patent and exclusivity expiry of a significant number of innovator drugs, biosimilars will become more popular. The Centre’s weekly analysis discusses the impact of biosimilars on the pharmaceutical industry, and examines the challenges posed to the regulatory systems worldwide. It also ponders on whether Hong Kong should review its regulations of pharmaceutical products.

The full version of the commentary is in Chinese only.